NTU Announces Results of AZ Plus Moderna Trial 新冠疫苗混打爭議 多家醫院投入試驗

The combination of AZ plus Moderna vaccines is more effective than two doses of AZ, according to National Taiwan University Hospital's experiment result.

National Taiwan University recently administered a mixed dose of AZ plus Moderna to 200 test subjects. The subjects' antibody levels were tested four weeks after their second dose. Based on the preliminary results, the mixed dose produced more antibodies than two doses of AZ with similar results to foreign trials in which subjects were given a mixed dose of AZ and BNT.

Lee Ping-ing, Advisor, Central Epidemic Command Center："You only produce adenovirus antibodies after a first dose (of AZ). This results in slightly lower activity levels with the second dose and makes it less effective. So, if you use another platform for your second dose -- if you don't use an adenovirus platform for your second dose -- whether you get BNT or Moderna (for your second dose), it will be more slightly more effective than getting two AZ doses."

NTU also experimented with mixed doses of Moderna and Medigen, Medigen and BNT, and AZ and BNT. The results for these are not yet available. Government-run Taoyuan Hospital, meanwhile, is experimenting with giving 200 people a third booster shot of Medigen after two doses of AZ. Chang Gung Memorial Hospital, on the other hand, is conducting AZ plus Moderna and AZ plus Medigen trials. 

Chiu Cheng-hsun, Vice Superintendent, Linkou Chang Gung Memorial Hospital："Groups that will get priority (for mixed doses) include medical personnel and caregivers. After (the Central Epidemic Command Center) approved mixed-dose trials, we started administering AZ plus Moderna. Dr. Chen has also experimented with AZ plus Medigen."

The hospitals will follow up with test subjects and test their antibody levels after three to six months. Meanwhile, experts say whether mixed doses can become available to the public will depend on vaccine supply and if the Central Epidemic Command Center allows it.

國內新冠疫苗混打，終於有初步成果！台大醫院日前完成「AZ+莫德納」混打試驗收案，共收200人，已完成第二劑接種後、滿28天的追蹤抽血，初步看來，混打抗體表現比打兩劑AZ佳，效果與國外「AZ+BNT」混打的保護力數據相當。

中央流行疫情指揮中心專家諮詢小組委員 李秉穎表示：「(AZ)打第一劑以後，才會產生腺病毒抗體，會使得第二劑的活性，腺病毒疫苗的效果稍微差一點。所以你第二劑，如果用其他的平台，就不用腺病毒的平台去打疫苗。不管是打BNT疫苗，或者是打莫德納疫苗，它的效果，都會比打兩劑AZ疫苗，來得高一點點。」

台大醫院進行中的混打試驗，還包括「莫德納+高端」、「高端+BNT」、「AZ+BNT」等，還在收案試驗中；衛福部立桃園醫院已展開第三劑接種高端疫苗試驗，以「AZ+AZ+高端」分組，受試者200人，已有一半完成接種；長庚醫院也有兩組混打研究進行，除了「AZ+莫德納」，還有「AZ+高端」。

林口長庚醫院副院長 邱政洵表示：「第一優先的這群(混打)，比如說醫療照護人員，之前(指揮中心)同意用混打嘛，所以我們有一組是AZ+莫德納的。那另外陳醫師還做了一個，就是AZ+高端 當作第二劑這樣。」

專家表示，各種不同混打研究，都將追蹤3個月到半年，再檢測中和抗體效價，所有研究成果都會送交指揮中心做參考；至於是否開放民眾混打，還得看疫苗到貨量，由指揮中心統籌規劃。